Document Detail


Serum lipid and blood pressure responses to quercetin vary in overweight patients by apolipoprotein E genotype.
MedLine Citation:
PMID:  20032478     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Our objective was to examine the effect of a quercetin supplementation on blood pressure, lipid metabolism, markers of oxidative stress, inflammation, and body composition in an at-risk population of 93 overweight-obese volunteers aged 25-65 y with metabolic syndrome traits in relation to apolipoprotein (apo) E genotype. Participants were randomized to receive 150 mg/d quercetin in a double-blinded, placebo-controlled, crossover trial with 6-wk treatment periods separated by a 5-wk washout period. Retrospectively, 5 apoE genotype variants were found (epsilon2/epsilon3, n = 3; epsilon3/epsilon3, n = 60; epsilon3/epsilon4, n = 23; epsilon2/epsilon4, n = 4; and epsilon4/epsilon4, n = 3). Participants were classified into the following 3 apoE phenotypes: apoE2 (n = 3), apoE3 (n = 60), and apoE4 (n = 26). Data were analyzed for apoE3 and apoE4 subgroups. Quercetin decreased systolic blood pressure by 3.4 mm Hg (P < 0.01) in the apoE3 group, whereas no significant effect was observed in the apoE4 group. Quercetin decreased serum HDL cholesterol (P < 0.01) and apoA1 (P < 0.01) and increased the LDL:HDL cholesterol ratio (P < 0.05) in the apoE4 subgroup, whereas the apoE3 subgroup had no significant changes in these variables. Quercetin significantly decreased plasma oxidized LDL and tumor necrosis factor-alpha in the apoE3 and apoE4 groups, whereas no significant inter-group differences were found. Serum C-reactive protein and nutritional status (body weight, waist circumference, fat mass, fat-free mass) were unaffected compared with placebo. In conclusion, quercetin exhibited blood pressure-lowering effects in overweight-obese carriers of the apo epsilon3/epsilon3 genotype but not in carriers of the epsilon4 allele. Furthermore, quercetin supplementation resulted in a reduction in HDL cholesterol and apoA1 in apo epsilon4 carriers.
Authors:
Sarah Egert; Christine Boesch-Saadatmandi; Siegfried Wolffram; Gerald Rimbach; Manfred J Müller
Related Documents :
6752638 - Decrease of lipoprotein lipase activity in skeletal muscle in man during a short-term c...
2736568 - Effects of pindolol on serum lipids, apolipoproteins, and lipoproteins in patients with...
10898048 - Dyslipidemia in peritoneal dialysis--relation to dialytic variables.
3121778 - Quantitative abnormalities of lipoprotein particles in multiple myeloma.
6947078 - Response of growth-retarded, hypophagic-hypodipsic rats with dorsomedial hypothalamic l...
10762668 - Low dose anandamide affects food intake, cognitive function, neurotransmitter and corti...
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't     Date:  2009-12-23
Journal Detail:
Title:  The Journal of nutrition     Volume:  140     ISSN:  1541-6100     ISO Abbreviation:  J. Nutr.     Publication Date:  2010 Feb 
Date Detail:
Created Date:  2010-01-21     Completed Date:  2010-02-04     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0404243     Medline TA:  J Nutr     Country:  United States    
Other Details:
Languages:  eng     Pagination:  278-84     Citation Subset:  IM    
Affiliation:
Institute of Nutrition and Food Science, Nutritional Physiology, University of Bonn, 53115 Bonn, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Antioxidants / pharmacology*,  therapeutic use
Apolipoproteins E / blood,  genetics*
Blood Pressure / drug effects*,  genetics
Cholesterol, HDL / blood,  genetics
Cholesterol, LDL / drug effects,  genetics
Cross-Over Studies
Double-Blind Method
Female
Humans
Male
Middle Aged
Obesity / blood,  drug therapy,  genetics*
Phenotype
Phytotherapy
Plant Extracts / pharmacology*,  therapeutic use
Polymorphism, Single Nucleotide*
Quercetin / pharmacology*,  therapeutic use
Tumor Necrosis Factor-alpha / blood,  genetics
Chemical
Reg. No./Substance:
0/Antioxidants; 0/Apolipoproteins E; 0/Cholesterol, HDL; 0/Cholesterol, LDL; 0/Plant Extracts; 0/Tumor Necrosis Factor-alpha; 117-39-5/Quercetin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Leptin Receptor Polymorphisms Interact with Polyunsaturated Fatty Acids to Augment Risk of Insulin R...
Next Document:  A Bovine Whey Protein Extract Stimulates Human Neutrophils to Generate Bioactive IL-1Ra through a NF...